newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Total net revenue of $15.2 millionAdjusted EBITDA1 of $ million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA™ extended-release